2001
Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin
Soares J, van Dyck C, Tan P, Zoghbi S, Garg P, Soufer R, Baldwin R, Fujita M, Staley J, Fu X, Amici L, Seibyl J, Innis R. Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin. Psychiatry Research 2001, 106: 81-93. PMID: 11306248, DOI: 10.1016/s0925-4927(01)00071-3.Peer-Reviewed Original ResearchConceptsTest/retest reproducibilityPositron emission tomographyCortical brain areasIntra-class correlation coefficientRetest reproducibilityBrain areasBrain measuresHealthy human subjectsMean intra-class correlation coefficientOutcome measuresConstant infusionParent tracerBlood measurementsEmission tomographyNeuropsychiatric disordersPET measuresReceptorsHuman subjectsPET acquisitionMean intraEquilibrium imagingImaging methodInfusionBolusRTComparison of [18F]altanserin and [18F]deuteroaltanserin for PET imaging of serotonin2A receptors in baboon brain: pharmacological studies
Staley J, Van Dyck C, Tan P, Tikriti M, Ramsby Q, Klump H, Ng C, Garg P, Soufer R, Baldwin R, Innis R. Comparison of [18F]altanserin and [18F]deuteroaltanserin for PET imaging of serotonin2A receptors in baboon brain: pharmacological studies. Nuclear Medicine And Biology 2001, 28: 271-279. PMID: 11323237, DOI: 10.1016/s0969-8051(00)00212-2.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAnimalsBrainDeuteriumFemaleFluorine RadioisotopesKetanserinPapioRadiochemistryReceptors, SerotoninTomography, Emission-ComputedConceptsReceptor antagonist SR 46349BSerotonin2A receptorsSR 46349BReceptor radiotracerPharmacological specificityTime-activity curvesConstant infusionBaboon brainCortical activityDistribution volumePharmacological studiesPET imagingRadiotracerBrainReceptorsBaboonsPET imagesRegional distributionFenfluramineInfusionBolusNeuroimaging in alzheimer’s disease: Relevance for treatment
van Dyck C. Neuroimaging in alzheimer’s disease: Relevance for treatment. Current Psychiatry Reports 2001, 3: 13-19. PMID: 11177754, DOI: 10.1007/s11920-001-0066-2.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseAD patientsRegional cerebral glucose metabolismRegional cerebral blood flowApolipoprotein E e4 alleleAnti-amyloid therapiesCerebral glucose metabolismDisease-modifying agentsCentral cholinergic neurotransmissionWhole brain atrophyCerebral blood flowPutative disease-modifying agentsWidespread clinical testingStructural magnetic resonanceBrain atrophyPrevention therapyInvestigational trialsAsymptomatic subjectsEfficacy measuresCholinergic neurotransmissionE4 alleleSenile plaquesDrug dosingOutcome measuresBlood flow
2000
Equilibrium modeling of 5-ht2a receptors with [18f]deuteroaltanserin and pet: feasibility of a constant infusion paradigm
van Dyck C, Soares J, Tan P, Staley J, Baldwin R, Amici L, Fu X, Garg P, Seibyl J, Charney D, Innis R. Equilibrium modeling of 5-ht2a receptors with [18f]deuteroaltanserin and pet: feasibility of a constant infusion paradigm. Nuclear Medicine And Biology 2000, 27: 715-722. PMID: 11150702, DOI: 10.1016/s0969-8051(00)00160-8.Peer-Reviewed Original ResearchConceptsSpecific brain uptakeConstant infusion paradigmBrain uptakeInfusion paradigmConstant infusionPromising positron emission tomography (PET) ligandPositron emission tomography (PET) ligandVenous blood samplingHealthy male subjectsSerotonin 2A receptorStable radiotracerCerebellar ratioInfusion periodBlood samplingTomography ligandH postinjectionTime-activity curvesParent tracerLinear regression analysisMale subjectsPET radioligandSlow metabolismHuman subjectsBrain activityRegression analysis